Notably, the inhibition of NOX1 was sufficient to prevent the dissociation of Trx1 from ASK1 and hence the activation of ASK1/JNK, implying that targeting this pathway is likely to be a promising strategy for the treatment of breast cancer. Here, MAP3K5 is linked to breast cancer.